Apton Biosystems, Inc., a Pleasanton, CA-based developer of Super-Res sequencing and single-molecule detection systems for large-scale clinical applications, such as early cancer detection and population sequencing, closed a $24m Series A financing.
The round was led by Kern Capital with participation by new and existing investors including Casdin Capital and Khosla Ventures. Concurrent with the financing, Jay Kern of Kern Capital has joined Apton’s board of directors.
The company intends to use the funds to continue developing its Super-Res sequencing and single-molecule proteomics detection systems.
Led by John Hanna, CEO, Apton Biosystems is a developer of Super-Res™ sequencing and single-molecule detection systems for large-scale clinical applications such as early cancer detection and population sequencing. Its Super-Res™ technology sequences tens of billions of reads in a single run using simple, un-patterned flow cells that lower variable costs.